Liver-Biliary-Pancreatic Center and the Liver, Digestive Disease and Metabolism Laboratory, Carolinas Medical Center, Charlotte, North Carolina 28232-2861, USA.
Gastroenterology. 2010 May;138(5):1909-19. doi: 10.1053/j.gastro.2009.11.001. Epub 2009 Nov 10.
BACKGROUND & AIMS: The nonstructural 5A (NS5A) protein of hepatitis C virus (HCV) plays a critical role in HCV replication and is an attractive target for the therapy of HCV infection. So far, little is known about the posttranslational regulation of NS5A protein and its precise role in HCV RNA replication. Our objectives were to elucidate the down-regulation of NS5A protein and HCV RNA replication by zinc mesoporphyrin (ZnMP) and the mechanism by which this process occurs.
Human hepatoma cells expressing HCV proteins were used to investigate the posttranslational regulation of ZnMP on NS5A protein by Western blots and immunoprecipitation. Real-time quantitative reverse transcription polymerase chain reaction was used to determine the effects of ZnMP on HCV RNA replication.
ZnMP selectively and markedly down-regulated NS5A protein levels by increasing degradation of NS5A protein (half-life fell from 18.7 hours to 2.7 hours). The proteasome inhibitors epoxomicin and MG132 significantly abrogated degradation of NS5A protein by ZnMP without affecting levels of NS5A in the absence of ZnMP. Analysis of immunoprecipitates with an antiubiquitin antibody revealed polyubiquitination of NS5A, suggesting that ZnMP induces ubiquitination of NS5A protein. In addition, 10 micromol/L of ZnMP reduced HCV replication by approximately 63% in the Con1 replicon cells, approximately 70% in J6/Japanese fulminant hepatitis 1 HCV-transfected cells, and approximately 90% in J6/Japanese fulminant hepatitis 1 HCV-infected cells without affecting cell viability.
ZnMP produces a rapid and profound down-regulation of the NS5A protein by enhancing its polyubiquitination and proteasome-dependent catabolism. ZnMP may hold promise as a novel agent to treat HCV infection.
丙型肝炎病毒(HCV)的非结构 5A(NS5A)蛋白在 HCV 复制中起着关键作用,是 HCV 感染治疗的一个有吸引力的靶点。到目前为止,人们对 NS5A 蛋白的翻译后调控及其在 HCV RNA 复制中的精确作用知之甚少。我们的目的是阐明锌卟啉(ZnMP)对 NS5A 蛋白的下调及其作用机制。
使用表达 HCV 蛋白的人肝癌细胞,通过 Western blot 和免疫沉淀来研究 ZnMP 对 NS5A 蛋白的翻译后调控。实时定量逆转录聚合酶链反应(PCR)用于确定 ZnMP 对 HCV RNA 复制的影响。
ZnMP 通过增加 NS5A 蛋白的降解,选择性和显著地下调 NS5A 蛋白水平(半衰期从 18.7 小时降至 2.7 小时)。蛋白酶体抑制剂环氧霉素和 MG132 显著阻止 ZnMP 降解 NS5A 蛋白,但不影响没有 ZnMP 时 NS5A 的水平。用抗泛素抗体分析免疫沉淀物显示 NS5A 的多泛素化,表明 ZnMP 诱导 NS5A 蛋白的泛素化。此外,10 μmol/L 的 ZnMP 使 Con1 复制子细胞中的 HCV 复制减少约 63%,J6/日本暴发性肝炎 1 HCV 转染细胞中的 HCV 复制减少约 70%,J6/日本暴发性肝炎 1 HCV 感染细胞中的 HCV 复制减少约 90%,而不影响细胞活力。
ZnMP 通过增强 NS5A 的多泛素化和蛋白酶体依赖性分解代谢,迅速而深刻地下调 NS5A 蛋白。ZnMP 可能成为治疗 HCV 感染的一种新型药物。